IVX
Director Trades
| Date | Director | Value |
|---|
Company News
Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial
Invion (ASX: IVX) has reported no adverse events from the application and use of its lead drug candidate INV043 on the first six patients of a Phase I/II non-melanoma skin cancer (NMSC) trial in Queensland. Data from a safety review committee (SRC) suggested that treatment with the novel photosensitiser was well-tolerated and feedback from clinicians […]
Weekly wrap: shares take a breather as Wall Street finds caution
Australia’s share market took a breather on Friday as Wall Street turned cautious about whether the Federal Reserve will continue to cut interest rates this month. By the close of trade the ASX 200 had dropped 0.6% or 54 points to 8420.9 points with only one of the 11 sectors closing up. The fall meant […]
Invion commences dosing in INV043 trial to treat non-melanoma skin cancer
Clinical-stage life sciences company Invion (ASX: IVX) has dosed the first patient in its Phase I/II non-melanoma skin cancer (NMSC) trial using active pharmaceutical ingredient and lead candidate INV043. The trial will aim to evaluate the safety and efficacy of the topically applied INV043, a novel photosensitiser developed in Australia for use in photodynamic therapy […]
Weekly wrap: record close as investors bet on a soft landing
Continuing optimism that the world economy is heading for a soft landing helped to push the Australian share market to a fresh record high to close the week. Despite some early indecision, the consensus on the US Federal Reserve’s bold move to cut a full 0.5% off official interest rates seems to be that it […]
Invion’s INV043 candidate demonstrates positive results in Phase II prostate cancer trial
Life sciences group Invion (ASX: IVX) has announced that its photodynamic technology (PDT) partner RMW Cho Group has completed a Phase II prostate cancer trial using its active pharmaceutical ingredient and lead cancer candidate INV043. The trial used six treatment cycles of INV043 as a monotherapy and a laser probe to apply red light to […]
Invion has productive quarter following $4.5m capital raise for next-gen photodynamic therapy to treat billion-dollar diseases
Life sciences group Invion Group (ASX: IVX) has progressed the development of its next-generation photodynamic therapy for the treatment of various illnesses, boosted by part proceeds of a $4.5 million capital raising. In June, the company signed an agreement with RMW Cho Group to co-develop the latter’s Photosoft technology for the treatment of atherosclerosis and […]
Invion to raise $15m to fund ongoing Photosoft technology development and expand market reach
Life sciences company Invion (ASX: IVX) is raising $15 million to continue developing the Photosoft technology and expand its addressable markets for treating cancer and related diseases using the next generation technology. Invion has executed conditional agreements with RMW Cho Group to co-develop Photosoft, which is an improved next generation photodynamic therapy for treating cancer and other […]
Study shows Invion’s INV043 could regress triple negative breast cancer tumours
A pilot proof-of-concept study by life sciences company Invion (ASX: IVX) has shown a complete regression of triple negative breast cancer (TNBC) in vivo following treatment with lead active pharmaceutical ingredient INV043. Conducted by Invion research partner Hudson Institute of Medical Research, the study used immuno-competent mice implanted with TNBC, establishing solid tumours in the […]
Invion Group eyes multiple applications for next-generation photodynamic therapy
While Invion Group (ASX: IVX) progresses its next-generation photodynamic therapy INV043 for treating cancers, it is also advancing the therapy’s potential in combating bacterial, viral, fungal, parasitic diseases and atherosclerosis, which causes heart problems. In June this year, Invion executed a co-development agreement with RMW Cho Group to further develop Invion’s Photosoft technology for treating […]
Invion advances ‘exciting’ photodynamic therapy to treat a range of cancers
Life sciences company Invion Group (ASX: IVX) is rapidly advancing its next-generation photodynamic therapy INV043 for treating numerous cancers. The drug is under development in collaboration with the world-leading Hudson Institute of Medical Research in Victoria. Dr Andrew Stephens from Hudson Institute said Invion’s INV043 was “exciting” and a “brand new way to treat cancers” […]
